“SinoVeda is an outstanding example of Edmonton’s flourishing biotechnology sector. We provide a nurturing environment, complemented by facilities and services, to develop and diversify Edmonton’s economy,” said Candace Brinsmead
Edmonton, AB (PRWEB) March 24, 2010
Edmonton Research Park based company Sino Veda is revolutionizing herbal remedies by using only natural ingredients and advanced manufacturing techniques. Although herbal remedies have been used around the world for centuries, only recently has modern medicine been able to capture the full potential of these natural ingredients.
“Natural products have received bad press over the years because of concerns about quality,” said Nuzhat Tam-Zaman, pharmacokinetics expert and co-founder of SinoVeda. “To obtain the highest levels of safety and purity, our ‘Pharmaceutical Platform Technology’ production method ensures every dose has the same amount of absorbable ingredients.” For consumers, this example of Edmonton innovation results in an end product that is purer, safer and standardized.
“We know nature has a lot to offer,” says Tam-Zaman. “We discovered in our research that ingredients in herbs have multiple functions and, at times, act synergistically together. We have a systematic approach to identifying and quantifying these ingredients. As well, our products undergo rigorous quality control tests before we manufacture them.” SinoVeda’s current product line includes Echinacea, Ginkgo Biloba, Panax Ginseng, St. John’s Wort, Lingzhi and Cordyceps, to be released in Canada in April.
The company’s newest product promises to shake up the studies of bone health and osteoporosis at the Edmonton research centre. Pearlium is a patent-pending formula containing vitamin D, magnesium, zinc and a form of highly soluble calcium acetate extracted from oyster pearls. Through SinoVeda’s production technique, the daily dosage of calcium in Pearlium is 300 mg compared to 1,000 mg in traditional supplements. The product is expected to enter the market this summer, followed by a clinical trial to test its effectiveness in treating postmenopausal women with osteoporosis.
Based at the 138-hectare Edmonton Research Park since 2007, SinoVeda has been a tenant in the Biotechnology Business Development Centre, a multi-tenant facility that provides emerging biotechnology firms with developed wet lab and office space at below-market lease rates and flexible lease terms, making scientific research in Edmonton extremely appealing.
“SinoVeda is an outstanding example of Edmonton’s flourishing biotechnology sector. We provide a nurturing environment, complemented by facilities and services, to develop and diversify Edmonton’s economy,” said Candace Brinsmead, Vice-President of Technology Advancement at the research park. “The Edmonton Research Park has been very beneficial in providing the amount of lab space we need. The cost is competitive and the environment is very encouraging,” said Tam-Zaman.
For additional information on the Edmonton Research Park, visit http://www.edmonton.com.